Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematology
•
Infectious Disease
•
Allergy & Immunology
•
Dermatology
•
Internal Medicine
What is your diagnostic approach to mild, chronic eosinophilia with AEC <1500?
When would a patient qualify for anti-IL5 therapy?
How to choose between IL-4, IL-5, or IL-13?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Do you routinely recommend transition to dual PO antibiotic coverage for strep species and MRSA, for patients with purulent cellulitis and in the absence of culture data?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Do you recommend lifelong antibiotic prophylaxis, or do you prefer a more selective approach based on risk factors in asplenic patients without a history of severe infections?
What treatments do you consider for cholinergic urticaria refractory to high dose H1 blockers and omalizumab?
Would you still consider omalizumab for CSU with angioedema in a patient with Factor V Leiden deficiency?
What is your preferred oral regime with duration for treatment of onychomycosis?
How do you reassure families that no allergy testing is needed for urticaria?
What is your experience using sucrosomial iron for symptomatic iron deficient patients who are intolerant of ferrous sulfate and prefer an oral regimen?
Do you perform genetic testing when patients have persistent hypogammaglobulinemia after rituximab therapy?